Product
SHR-1316
5 clinical trials
1 drug
5 indications
Indication
Cervical CancerIndication
Small Cell Lung CancerIndication
Advanced MalignanciesIndication
Breast CancerIndication
Limited-Stage Small Cell Lung CancerDrug
SHR-1316Clinical trial
A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical CancerStatus: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Phase Ⅰb/Ⅱ Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2022-01-15
Clinical trial
A Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Efficacy of SHR-1501 in Combination With SHR-1316 in Patients With Advanced MalignanciesStatus: Completed, Estimated PCD: 2023-01-12
Clinical trial
Study to Evaluate the Efficacy and Safety of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment for Patients With Triple-negative and Hormone Receptor-positive, HER2-negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Comparing the Efficiency Between Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer: a Randomized, Controlled, Open-label, Single-center Phase III Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2027-08-01